N
Nomic Bio
Develop the next generation of proteomic tools to better understand,detect and treat diseases
About Nomic Bio
Nplex Biosciences operates in the biotechnology sector, specializing in the development of advanced proteomics solutions using nanotechnology. The company's core product, the nELISA, is a miniaturized and highly parallelized version of the classical sandwich ELISA immunoassay. This innovative platform allows for the scalable and cost-effective measurement of proteins, overcoming historical economic barriers associated with antibody-based proteomics. Nplex Biosciences primarily serves research teams in academic institutions, pharmaceutical companies, and biotech firms who require high-throughput protein profiling for their projects. The company generates revenue through the sale of its nELISA platform and associated consumables, as well as through service contracts for custom proteomics projects. By leveraging DNA nanotechnology, Nplex Biosciences has engineered a unique solution that deciphers the identity of proteins on micron-sized beads, enabling precise and efficient protein analysis. The market for Nplex Biosciences includes sectors focused on drug discovery, biomarker discovery, and personalized medicine. The business model is centered around providing a scalable and reliable proteomics platform that meets the high-throughput needs of its clients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Montreal, Canada
- Employees
- 105
- Open positions
- None listed
- Dealroom signal
- 83.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, YC W20, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2024 | $42M | $168M | Lux Capital · SR One · Amplitude Ventures · AVANT BIO | ↗ |
| SERIES AOther financing | Dec 2021 | $17M | $68M | Casdin Capital · Lux Capital · SR One | ↗ |
Growth signals
Latest recorded traffic for Nomic Bio is 32K monthly website visits, up 384.8% over the last three months. Nomic Bio's team grew 5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
2048 Ventures
Y Combinator
Series A6 investors entered at this stage
Casdin Capital
Lux Capital
SR One
Amplitude Ventures
AVANT BIO
Real Ventures
Other known investors2 additional known investors
McGill Research and Innovation
McGill University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nomic Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nomic Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.